Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease. Metabolon, Inc. has announced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback